Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) Selling, General, & Admin. Expense: ¥146.4 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:605177 Zhejiang East-Asia Pharmaceutical Co Ltd SHSE:605177
62 GF Score
Price ¥24.73
GF Value ¥19.24
Valuation Modestly Overvalued
! 9 Warning Signs
View Full Analysis

What is Zhejiang East-Asia Pharmaceutical Co Selling, General, & Admin. Expense?

Zhejiang East-Asia Pharmaceutical Co SHSE:605177 +0.16% 62 Selling, General, & Admin. Expense is ¥146.4 Mil as of Jun. 2026. GuruFocus rates SHSE:605177 with a GF Score™ of 62/100 and a GF Value™ of ¥19.24 (Modestly Overvalued). The stock has 9 warning signs investors should review.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Zhejiang East-Asia Pharmaceutical Co's selling, general, & admin. expense for the three months ended in Jun. 2026 was ¥39.5 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Jun. 2026 was ¥146.4 Mil.


Zhejiang East-Asia Pharmaceutical Co  (SHSE:605177) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Zhejiang East-Asia Pharmaceutical Co Selling, General, & Admin. Expense Related Terms


Zhejiang East-Asia Pharmaceutical Co Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for Zhejiang East-Asia Pharmaceutical Co's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhejiang East-Asia Pharmaceutical Co Selling, General, & Admin. Expense Chart

Zhejiang East-Asia Pharmaceutical Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only 105.70 111.80 135.93 166.56 145.65

Zhejiang East-Asia Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.39 36.94 35.52 34.48 39.46

SHSE:605177 vs VRTX, REGN, MRNA: Selling, General, & Admin. Expense Comparison

For the Biotechnology subindustry, Zhejiang East-Asia Pharmaceutical Co's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang East-Asia Pharmaceutical Co Selling, General, & Admin. Expense vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zhejiang East-Asia Pharmaceutical Co's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Zhejiang East-Asia Pharmaceutical Co's Selling, General, & Admin. Expense falls into.


SHSE:605177
62GF Score
Zhejiang East-Asia Pharmaceutical Co Ltd SHSE:605177
Selling, General, & Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zhejiang East-Asia Pharmaceutical Co Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥146.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of ¥146.4 Mil mean?
Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) has a Selling, General, & Admin. Expense of ¥146.4 Mil as of Jun. 2026. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Zhejiang East-Asia Pharmaceutical Co and its competitors.
Is Zhejiang East-Asia Pharmaceutical Co's Selling, General, & Admin. Expense too high?
Zhejiang East-Asia Pharmaceutical Co's current Selling, General, & Admin. Expense is ¥146.4 Mil. Overall, Zhejiang East-Asia Pharmaceutical Co has a GF Score™ of 62/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang East-Asia Pharmaceutical Co's Selling, General, & Admin. Expense compare to VRTX and REGN?
Zhejiang East-Asia Pharmaceutical Co's Selling, General, & Admin. Expense of ¥146.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Biotechnology company?
A good Selling, General, & Admin. Expense depends on the Biotechnology industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Zhejiang East-Asia Pharmaceutical Co and its competitors. Zhejiang East-Asia Pharmaceutical Co's current Selling, General, & Admin. Expense is ¥146.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang East-Asia Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥19.24, compared to a current price of ¥24.73 — trading 28.5% above its estimated fair value. The current Selling, General, & Admin. Expense is ¥146.4 Mil. Zhejiang East-Asia Pharmaceutical Co's overall GF Score™ is 62/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Zhejiang East-Asia Pharmaceutical Co (SHSE:605177), the current Selling, General, & Admin. Expense is ¥146.4 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) Overvalued in 2026?

Based on GuruFocus' analysis, Zhejiang East-Asia Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥24.73 is trading 28.5% above its estimated GF Value™ of ¥19.24. GuruFocus considers Zhejiang East-Asia Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SHSE:605177:

  • Selling, General, & Admin. Expense: ¥146.4 Mil
  • GF Value™: ¥19.24 vs. price of ¥24.73 (28.5% above fair value)
  • GF Score™: 62/100 with 9 warning signs

No single metric tells the full story. See the SHSE:605177 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zhejiang East-Asia Pharmaceutical Co Business Description

Address No. 118, Laodong North Road, 23rd Floor, Chamber of Commerce Building, Huangyan District, Zhejiang Province, Taizhou, CHN
Zhejiang East-Asia Pharmaceutical Co Ltd is mainly engaged in the production of bulk pharmaceutical chemicals, tablets, granules and capsules. The company's main products are: Ofloxacin, levofloxacin, loratadine hydrochloride, levofloxacin hydrochloride, trimebutine maleate, ketoconazole, terbinafine hydrochloride, piperazine, ticlazole and so on.
62GF Score

Get the complete analysis for SHSE:605177

Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥24.73
Price
¥19.24
GF Value